The net proceeds from the Private Placement will be used by Fort for general working capital purposes and to support the extension of a loan under a previously disclosed loan agreement. About Jeffs' Brands Tel Aviv, Israel, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd ("Jeffs' Brands" or the "Company") (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, today announced that Fort Technology Inc. ("Fort") (TSXV: FORT), a TSX Venture Exchange-listed company in wh ...

Core Viewpoint - Galleon Gold Corp. has successfully closed the second and final tranche of its non-brokered private placement offering of convertible debentures, raising a total of $7,500,000 for its West Cache Gold Project and general working capital [1][4]. Offering Details - The offering consists of 20 convertible debentures with gross proceeds of $1,000,000 from this tranche [1]. - The debentures have a term of 36 months and bear an interest rate of 8.0% per annum, payable in cash or common shares at the investor's option [2]. - The conversion price for the debentures is set at $0.30 per common share [2]. Conversion Terms - Holders of the debentures can convert any portion of the principal into common shares at the conversion price during the term [3]. - If converted before the term ends, accrued interest will be payable in common shares based on the higher of the average closing price of the last 20 trading days or the closing market price [3]. Finder's Fees - The company paid finders' fees consisting of a cash commission of $60,000 and 200,000 non-transferrable finders' warrants, each allowing the holder to acquire one common share at $0.36 over a two-year period [4]. Use of Proceeds - Proceeds from the offering will be utilized for exploration and advancement of the West Cache Gold Project in Timmins, Ontario, as well as for general working capital [4]. Regulatory Compliance - The debentures and any underlying common shares will be subject to a hold period of four months and one day from the closing date, in accordance with applicable securities laws [5].

Core Viewpoint - Optimi Health Corp. has announced a non-brokered private placement of CAD$3.45 million through the issuance of unsecured convertible debentures and an extension of a secured term loan, aimed at enhancing its working capital and financial flexibility [1][3]. Group 1: Convertible Debentures - The company plans to issue 3,450 unsecured convertible debentures at a price of CAD$1,000 each, totaling gross proceeds of CAD$3,450,000 [1]. - The convertible debentures will have an interest rate of 15.0% per annum, payable quarterly, and will mature in 12 months, extendable for an additional 12 months [1][2]. - The conversion price for the debentures is set at $0.15, based on the closing price of the common shares prior to the subscription agreement [1][2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general working capital purposes [3]. - All securities issued will be subject to a hold period of four months and a day from the issuance date, in compliance with CSE rules [3]. Group 3: Related Party Transactions - The offering constitutes a related party transaction, involving the CEO and Chair of the Board as investors, with their respective holdings post-acquisition being 12.29% and 8.52% of the company [3]. - The company is relying on exemptions from certain valuation and minority shareholder approval requirements due to the fair market value of the insiders' participation not exceeding 25% of the company's market capitalization [3]. Group 4: Secured Term Loan - The company has extended a non-dilutive debt financing agreement for CAD$1,000,000, secured against its assets, with a new maturity date of April 30, 2026 [4][5]. - The loan bears an interest rate of 7.5% per annum, payable quarterly, and the company can repay the loan at any time with prior notice [5]. - As part of the loan extension, the company has granted 400,000 common share purchase warrants, exercisable at $0.25 per share for two years [5]. Group 5: Company Overview - Optimi Health Corp. is a Health Canada-licensed manufacturer of GMP-compliant natural psilocybin and MDMA, focusing on high-quality psychedelic products to support mental health therapies [6].

Core Viewpoint - Atrium Mortgage Investment Corporation has announced an agreement to issue $30 million in 6.00% convertible unsecured subordinated debentures, with an option for an additional $4.5 million, to repay existing debt and fund future mortgage opportunities [1][2]. Group 1: Offering Details - The offering consists of 6.00% convertible unsecured subordinated debentures due September 30, 2032, priced at $1,000 each [1]. - The total gross proceeds could reach $34.5 million if the over-allotment option is fully exercised [1]. - The expected closing date for the offering is around June 30, 2025, pending necessary approvals [2]. Group 2: Debenture Terms - The debentures will accrue interest at 6.00% per annum, payable semi-annually starting March 31, 2026 [3]. - Holders can convert the debentures into common shares at a conversion price of $13.65, subject to adjustments [3]. - The debentures are direct, unsecured obligations of Atrium and are subordinated to other senior debts [4]. Group 3: Redemption and Repayment - The debentures are not redeemable before September 30, 2028, with specific conditions for redemption thereafter [5]. - Atrium has the right to repay the principal amount through the issuance of common shares, and can also pay interest in common shares [6]. Group 4: Company Overview - Atrium is a non-bank provider of residential and commercial mortgages, focusing on major urban centers in Canada [9]. - The company aims to provide stable dividends and preserve shareholder equity by adhering to conservative risk parameters [9]. - Atrium operates as a Mortgage Investment Corporation (MIC) under Canadian tax law, allowing it to avoid taxation on income if distributed as dividends [10].